SlideShare a Scribd company logo
1 of 15
IG A NEPHROPATHY
GAYATHRI THAMPATTY
PGY2
• MOST COMMON LESION FOUND TO CAUSE
PRIMARY GLOMERULONEPHRITIS THROUGHOUT
MOST DEVELOPED COUNTRIES OF THE WORLD
• MAY PRESENT AT ANY AGE, PEAK INCIDENCE IN THE
SECOND AND THIRD DECADES OF LIFE. THERE IS
APPROXIMATELY A 2:1 MALE TO FEMALE
PREDOMINANCE IN NORTH AMERICAN AND
WESTERN EUROPEAN POPULATIONS
• THE REPORTED INCIDENCE OF MESANGIAL IGA DEPOSITION IN APPARENTLY
HEALTHY INDIVIDUALS RANGES FROM 3 TO 16 PERCENT . THESE CASES HAD
NO CLINICAL FEATURES OF NEPHRITIS BUT THEIR RENAL BIOPSY WAS
CONSISTENT WITH IGA NEPHROPATHY.
• THIS OBSERVATION RAISES THREE IMPORTANT POINTS:
●THERE IS A LARGE COHORT OF UNDIAGNOSED "LATENT" IGA
NEPHROPATHY IN THE GENERAL POPULATION.
●THIS MUST BE TAKEN INTO ACCOUNT WHEN GENETIC STUDIES ARE
UNDERTAKEN COMPARING GENE POLYMORPHISMS IN IGA NEPHROPATHY
WITH NORMAL "HEALTHY" POPULATIONS.
●PROCESS OF MESANGIAL IGA DEPOSITION IS LIKELY TO BE SEPARATE
FROM THE INDUCTION OF GLOMERULAR INJURY AND IGA DEPOSITION DOES
NOT NECESSARILY NEED TO BE FOLLOWED BY NEPHRITIS-
IGA DEPOSITION IN OTHER FORMS OF
GLOMERULONEPHRITIS- THIN BASEMENT MEMBRANE
NEPHROPATHY, LUPUS NEPHRITIS, MINIMAL CHANGE
DISEASE, AND DIABETIC NEPHROPATHY. MOST PROBABLY
DUE TO CHANCE ASSOCIATIONS, SINCE IGA DEPOSITION IS
COMMON IN THE GENERAL POPULATION
LUPUS NEPHRITIS COULD ALSO HAVE ASSOCIATED
PROMINENT MESANGIAL IGA DEPOSITION. LUPUS CAN BE
DISTINGUISHED FROM IGA NEPHROPATHY
HISTOLOGICALLY BY THE MORE PROMINENT DEPOSITION
OF IGG THAN IGA AND THE PRESENCE OF SUBSTANTIAL
C1Q DEPOSITION, INDICATING ACTIVATION OF THE
CLASSIC COMPLEMENT PATHWAY, AS OPPOSED TO THE
ALTERNATE PATHWAY ACTIVATION IN IGA NEPHROPATHY
LIGHT MICROSCOPY
• MAJOR FINDING - FOCAL (INVOLVING LESS THAN 50
PERCENT OF GLOMERULI) OR MORE OFTEN
DIFFUSE MESANGIAL PROLIFERATION AND MATRIX
EXPANSION
ELECTRON MICROSCOPY
• ELECTRON-DENSE DEPOSITS THAT ARE
PRIMARILY LIMITED TO THE MESANGIUM (WHICH
ARE OUTSIDE OF MESANGIAL CELLS IN THE
MESANGIAL SPACES) BUT MAY ALSO OCCUR IN
THE SUBENDOTHELIAL AND SUBEPITHELIAL
SPACES. THE NUMBER AND SIZE OF THESE
DEPOSITS GENERALLY CORRELATES WELL WITH
THE SEVERITY OF CHANGES SEEN ON LIGHT
MICROSCOPY
CLINICAL FEATURES
• APPROXIMATELY 40 TO 50 PERCENT - ONE OR RECURRENT EPISODES
OF VISIBLE HEMATURIA, USUALLY FOLLOWING A URI (SYNPHARYNGITIC
HEMATURIA). PATIENTS MAY COMPLAIN OF FLANK PAIN, LOW GRADE
FEVER- MIMIC URINARY TRACT INFECTION OR UROLITHIASIS. MOST
PATIENTS HAVE ONLY A FEW EPISODES OF VISIBLE HEMATURIA AND
EPISODES USUALLY RECUR FOR A FEW YEARS AT MOST.
• 30 TO 40 PERCENT HAVE MICROSCOPIC HEMATURIA AND USUALLY MILD
PROTEINURIA, AND ARE INCIDENTALLY DETECTED ON A ROUTINE
EXAMINATION . THESE PATIENTS, THE DISEASE IS OF UNCERTAIN
DURATION. GROSS HEMATURIA WILL EVENTUALLY OCCUR IN 20 TO 25
PERCENT OF THESE PATIENTS.
• LESS THAN 10 PERCENT PRESENT WITH EITHER NEPHROTIC SYNDROME
OR ACUTE RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS PICTURE
CHARACTERIZED BY EDEMA, HYPERTENSION, AND RENAL
INSUFFICIENCY AS WELL AS HEMATURIA. RARELY, IGA NEPHROPATHY
MAY PRESENT WITH MALIGNANT HYPERTENSION
• CIRRHOSIS, CELIAC DISEASE, AND HIV
INFECTION ARE ALL ASSOCIATED WITH A
HIGH FREQUENCY OF GLOMERULAR IGA
DEPOSITION
• NEPHROTIC SYNDROME IN IGA NEPHROPATHY -
USUALLY INDICATIVE OF ADVANCED DISEASE.
SOME PATIENTS HAVE AN ACUTE ONSET OF
THE NEPHROTIC SYNDROME IN WHICH THERE
IS ONLY MILD MESANGIAL PROLIFERATION ON
RENAL BIOPSY AND THE MOST PROMINENT
FINDING IS DIFFUSE FUSION OF THE FOOT
PROCESSES, SIMILAR TO THAT SEEN IN
MINIMAL CHANGE DISEASE . FURTHERMORE,
MANY OF THESE PATIENTS BEHAVE AS IF THEY
HAVE MINIMAL CHANGE DISEASE, WITH
REMISSION OF PROTEINURIA BEING INDUCED
BY GLUCOCORTICOID THERAPY.
INDICATIONS FOR RENAL BIOPSY
• A KIDNEY BIOPSY IS USUALLY
PERFORMED FOR THE EVALUATION OF
SUSPECTED IGA NEPHROPATHY ONLY IF
THERE ARE SIGNS SUGGESTIVE OF
MORE SEVERE OR PROGRESSIVE
DISEASE SUCH AS PROTEIN EXCRETION
ABOVE 0.5 TO 1 G/DAY, ELEVATED SERUM
CREATININE CONCENTRATION, OR
HYPERTENSION
• PATIENTS WHO HAVE RECURRENT EPISODES OF
GROSS HEMATURIA WITHOUT PROTEINURIA ARE
AT LOW RISK FOR PROGRESSIVE KIDNEY
DISEASE COMPARED WITH PATIENTS WHO HAVE
PERSISTENT MICROSCOPIC HEMATURIA AND
PROTEINURIA. IN ADDITION, ISOLATED
PERSISTENT HEMATURIA (IE, WITH LITTLE OR NO
PROTEINURIA) AT PRESENTATION MAY BE
ASSOCIATED WITH PROGRESSIVE DISEASE
OVER TIME
• ISOLATED HEMATURIA, NO OR MINIMAL PROTEINURIA (LESS THAN 500 TO 1000
MG/DAY), AND A NORMAL GLOMERULAR FILTRATION RATE (GFR) ARE TYPICALLY NOT
TREATED AND OFTEN NOT BIOPSIED AND THEREFORE NOT IDENTIFIED AS HAVING
IGA NEPHROPATHY. NEEDS PERIODIC MONITORING AT 6- TO 12-MONTH INTERVALS
SINCE THERE IS AN APPRECIABLE RATE OF PROGRESSIVE DISEASE AS
MANIFESTED BY INCREASES IN PROTEINURIA, BLOOD PRESSURE, AND/OR SERUM
CREATININE.
• ●PATIENTS WITH PERSISTENT PROTEINURIA (ABOVE 1 G/DAY OR PERHAPS ABOVE
500 MG/DAY), A NORMAL OR ONLY SLIGHTLY REDUCED GFR THAT IS NOT DECLINING
RAPIDLY, AND ONLY MILD TO MODERATE HISTOLOGIC FINDINGS ON RENAL BIOPSY
ARE INITIALLY MANAGED WITH NONIMMUNOSUPPRESSIVE THERAPIES TO SLOW
PROGRESSION.
• •ANGIOTENSIN INHIBITION WITH EITHER AN ACE INHIBITOR OR ARB. THE GOALS OF
THERAPY WITH AN ACE INHIBITOR OR ARB ARE A URINARY PROTEIN EXCRETION
BELOW 500 MG/DAY OR 1 G/DAY AND A BLOOD PRESSURE LESS THAN 130/80 MMHG.
• •FISH OIL (3.3 GRAMS/DAY OR MORE) CAN BE TRIED IN PATIENTS WITH PROTEIN
EXCRETION ABOVE 1 G/DAY DESPITE THREE TO SIX MONTHS OF THERAPY WITH AN
ACE INHIBITOR OR ARB.
THE INDICATIONS FOR THE USE OF
GLUCOCORTICOIDS ALONE OR IN
COMBINATION WITH OTHER
IMMUNOSUPPRESSIVE DRUGS• NOT WELL DEFINED
• MOST NEPHROLOGISTS DO NOT TREAT MILD, STABLE, OR VERY SLOWLY PROGRESSIVE IGA
NEPHROPATHY WITH GLUCOCORTICOIDS OR OTHER IMMUNOSUPPRESSIVE THERAPIES
• IN GENERAL, ANTI-INFLAMMATORY THERAPY WITH GLUCOCORTICOIDS IN PATIENTS WITH
CLINICAL FEATURES SUPPORTING ACTIVE DISEASE AND PROGRESSION, WHICH INCLUDE
HEMATURIA IN ADDITION TO ONE OR MORE OF THE FOLLOWING:
• ●A PROGRESSIVELY DECLINING GLOMERULAR FILTRATION RATE
• ●PERSISTENT PROTEINURIA ABOVE 1 G/DAY AFTER MAXIMAL ANTIPROTEINURIC THERAPY WITH
ACE INHIBITORS OR ARBS FOR THREE TO SIX MONTHS
• ●MORPHOLOGIC EVIDENCE OF ACTIVE DISEASE BASED ON KIDNEY BIOPSY (EG,
PROLIFERATIVE OR NECROTIZING GLOMERULAR CHANGES)
THANK YOU

More Related Content

What's hot

Membranoproliferative glomerulonephritis s
Membranoproliferative glomerulonephritis sMembranoproliferative glomerulonephritis s
Membranoproliferative glomerulonephritis s
Mohammad Manzoor
 
Nephrotic And Nephritic Syndrome 2008
Nephrotic And Nephritic Syndrome 2008Nephrotic And Nephritic Syndrome 2008
Nephrotic And Nephritic Syndrome 2008
Dang Thanh Tuan
 
Approach to the patient with Glomerular Disease.
Approach to the patient with Glomerular Disease.Approach to the patient with Glomerular Disease.
Approach to the patient with Glomerular Disease.
Sufindc
 
20100603 acute glomerulonephritis
20100603 acute glomerulonephritis20100603 acute glomerulonephritis
20100603 acute glomerulonephritis
Sumit Prajapati
 

What's hot (20)

Membranoproliferative glomerulonephritis s
Membranoproliferative glomerulonephritis sMembranoproliferative glomerulonephritis s
Membranoproliferative glomerulonephritis s
 
AGN
AGNAGN
AGN
 
Glomerulonephritis
GlomerulonephritisGlomerulonephritis
Glomerulonephritis
 
Glomerular diseases
Glomerular diseases Glomerular diseases
Glomerular diseases
 
Membranous Nephropathy - Dr. Gawad
Membranous Nephropathy - Dr. GawadMembranous Nephropathy - Dr. Gawad
Membranous Nephropathy - Dr. Gawad
 
Glomerular diseases
Glomerular diseasesGlomerular diseases
Glomerular diseases
 
nephritic and nephrotic syndrome
   nephritic and nephrotic syndrome   nephritic and nephrotic syndrome
nephritic and nephrotic syndrome
 
Nephrotic And Nephritic Syndrome 2008
Nephrotic And Nephritic Syndrome 2008Nephrotic And Nephritic Syndrome 2008
Nephrotic And Nephritic Syndrome 2008
 
IgA NEPHROPATHY (CLOSING THE LOOP) - Dr. Gawad
IgA NEPHROPATHY (CLOSING THE LOOP)  - Dr. GawadIgA NEPHROPATHY (CLOSING THE LOOP)  - Dr. Gawad
IgA NEPHROPATHY (CLOSING THE LOOP) - Dr. Gawad
 
Management of lupus nephritis
Management of lupus nephritisManagement of lupus nephritis
Management of lupus nephritis
 
Rapidly progressive glomerulonephritis
Rapidly progressive glomerulonephritisRapidly progressive glomerulonephritis
Rapidly progressive glomerulonephritis
 
Approach to the patient with Glomerular Disease.
Approach to the patient with Glomerular Disease.Approach to the patient with Glomerular Disease.
Approach to the patient with Glomerular Disease.
 
20100603 acute glomerulonephritis
20100603 acute glomerulonephritis20100603 acute glomerulonephritis
20100603 acute glomerulonephritis
 
Proteinuria & Hematuria
Proteinuria & HematuriaProteinuria & Hematuria
Proteinuria & Hematuria
 
Minimal Change Diseas
Minimal Change DiseasMinimal Change Diseas
Minimal Change Diseas
 
minimal change disease
minimal change diseaseminimal change disease
minimal change disease
 
Lupus nephritis 2016
Lupus nephritis 2016Lupus nephritis 2016
Lupus nephritis 2016
 
Acute post streptococcal glomerulonephritis
Acute post streptococcal glomerulonephritisAcute post streptococcal glomerulonephritis
Acute post streptococcal glomerulonephritis
 
Acute Glomerulonephritis (AGN) by Dr. Dilip
Acute Glomerulonephritis (AGN) by Dr. DilipAcute Glomerulonephritis (AGN) by Dr. Dilip
Acute Glomerulonephritis (AGN) by Dr. Dilip
 
IgA Nephropathy
IgA NephropathyIgA Nephropathy
IgA Nephropathy
 

Viewers also liked (16)

Ig a nefropati
Ig a nefropatiIg a nefropati
Ig a nefropati
 
Diagnostic Approach Ig A Nephropathy
Diagnostic Approach Ig A NephropathyDiagnostic Approach Ig A Nephropathy
Diagnostic Approach Ig A Nephropathy
 
Hematuria
HematuriaHematuria
Hematuria
 
Hematuria
Hematuria  Hematuria
Hematuria
 
GLOMERULONEPHRITIS:What is New
GLOMERULONEPHRITIS:What is NewGLOMERULONEPHRITIS:What is New
GLOMERULONEPHRITIS:What is New
 
17 february lupus nephritis prof ashraf fouda
17 february lupus nephritis prof ashraf fouda17 february lupus nephritis prof ashraf fouda
17 february lupus nephritis prof ashraf fouda
 
MPGN Pam
MPGN  PamMPGN  Pam
MPGN Pam
 
MPGN
MPGNMPGN
MPGN
 
Renal vasculitis
Renal vasculitisRenal vasculitis
Renal vasculitis
 
MPGN/MCGN
MPGN/MCGNMPGN/MCGN
MPGN/MCGN
 
Síndrome de Goodpasture
Síndrome de GoodpastureSíndrome de Goodpasture
Síndrome de Goodpasture
 
Hematuria
HematuriaHematuria
Hematuria
 
Hematuria
HematuriaHematuria
Hematuria
 
Hematuria
HematuriaHematuria
Hematuria
 
Hematuria
HematuriaHematuria
Hematuria
 
Pathology of Glomerulonephritis
Pathology of GlomerulonephritisPathology of Glomerulonephritis
Pathology of Glomerulonephritis
 

Similar to Ig a nephropathy

Similar to Ig a nephropathy (20)

CRF case study.pptx
CRF case study.pptxCRF case study.pptx
CRF case study.pptx
 
FSGS-Sparsentan.pptx
FSGS-Sparsentan.pptxFSGS-Sparsentan.pptx
FSGS-Sparsentan.pptx
 
cysticfibrosis.pptx
cysticfibrosis.pptxcysticfibrosis.pptx
cysticfibrosis.pptx
 
Nephrotic syndrome
Nephrotic syndrome Nephrotic syndrome
Nephrotic syndrome
 
Total parentral nutrition in cardiac surgery
Total parentral nutrition in cardiac surgeryTotal parentral nutrition in cardiac surgery
Total parentral nutrition in cardiac surgery
 
Non alcoholic fatty liver disease presentation
Non alcoholic fatty liver disease presentationNon alcoholic fatty liver disease presentation
Non alcoholic fatty liver disease presentation
 
Necrotizing enterocolitis in newborns
Necrotizing enterocolitis in newbornsNecrotizing enterocolitis in newborns
Necrotizing enterocolitis in newborns
 
Onychomycosis and diabetes
Onychomycosis and diabetesOnychomycosis and diabetes
Onychomycosis and diabetes
 
Neprotic syndrame
Neprotic syndrameNeprotic syndrame
Neprotic syndrame
 
Haematuria
HaematuriaHaematuria
Haematuria
 
ILD clinical update.pptx
ILD clinical update.pptxILD clinical update.pptx
ILD clinical update.pptx
 
nephrotic and nephritic syndrome
nephrotic and nephritic syndromenephrotic and nephritic syndrome
nephrotic and nephritic syndrome
 
Oligohydramnios and polyhydramnios
Oligohydramnios and polyhydramniosOligohydramnios and polyhydramnios
Oligohydramnios and polyhydramnios
 
Menopause part 1(overview)
Menopause part 1(overview)Menopause part 1(overview)
Menopause part 1(overview)
 
Eosinophilic GI Disorders
Eosinophilic GI DisordersEosinophilic GI Disorders
Eosinophilic GI Disorders
 
Nephrotic syndrome (1)
Nephrotic syndrome (1)Nephrotic syndrome (1)
Nephrotic syndrome (1)
 
L11-14. Disorders of the pituitary gland and adrenals.pptx
L11-14. Disorders of the pituitary gland and adrenals.pptxL11-14. Disorders of the pituitary gland and adrenals.pptx
L11-14. Disorders of the pituitary gland and adrenals.pptx
 
Porphyrias and lab diagnosis
Porphyrias and lab diagnosisPorphyrias and lab diagnosis
Porphyrias and lab diagnosis
 
acute inflammatory demyelinating polyneuropathy
acute inflammatory demyelinating polyneuropathyacute inflammatory demyelinating polyneuropathy
acute inflammatory demyelinating polyneuropathy
 
Poly Cystic Ovarian Syndrome By Dr. Vidhi Agarwal
Poly  Cystic  Ovarian  Syndrome By Dr. Vidhi AgarwalPoly  Cystic  Ovarian  Syndrome By Dr. Vidhi Agarwal
Poly Cystic Ovarian Syndrome By Dr. Vidhi Agarwal
 

More from pkhohl

Hyperaldosteronism 3 26-14
Hyperaldosteronism 3 26-14Hyperaldosteronism 3 26-14
Hyperaldosteronism 3 26-14
pkhohl
 
Refractory ARDS
Refractory ARDSRefractory ARDS
Refractory ARDS
pkhohl
 
TF route
TF routeTF route
TF route
pkhohl
 
Early surgery for infective endocarditis
Early surgery for infective endocarditisEarly surgery for infective endocarditis
Early surgery for infective endocarditis
pkhohl
 
Intern talk - BP and stroke
Intern talk - BP and stroke Intern talk - BP and stroke
Intern talk - BP and stroke
pkhohl
 
Surrogate decision making
Surrogate decision makingSurrogate decision making
Surrogate decision making
pkhohl
 
Asdpe disantis
Asdpe disantisAsdpe disantis
Asdpe disantis
pkhohl
 
Iabp 3 6-14
Iabp 3 6-14Iabp 3 6-14
Iabp 3 6-14
pkhohl
 
CNS vasculitis
CNS vasculitis CNS vasculitis
CNS vasculitis
pkhohl
 
Renal infarction morning report 2-10-2014
Renal infarction morning report 2-10-2014Renal infarction morning report 2-10-2014
Renal infarction morning report 2-10-2014
pkhohl
 
Pe massive wilfong
Pe massive wilfongPe massive wilfong
Pe massive wilfong
pkhohl
 
Hypertension- Classics Trobaugh
Hypertension- Classics TrobaughHypertension- Classics Trobaugh
Hypertension- Classics Trobaugh
pkhohl
 
Mediterranean diet primary prevention of cvd journal club
Mediterranean diet primary prevention of cvd journal clubMediterranean diet primary prevention of cvd journal club
Mediterranean diet primary prevention of cvd journal club
pkhohl
 
The challenge of the end of-life discussion housestaff 2014
The challenge of the end of-life discussion housestaff 2014The challenge of the end of-life discussion housestaff 2014
The challenge of the end of-life discussion housestaff 2014
pkhohl
 
Ai morning report 1 21-2014
Ai morning report 1 21-2014Ai morning report 1 21-2014
Ai morning report 1 21-2014
pkhohl
 
Hiv classics11252013
Hiv classics11252013Hiv classics11252013
Hiv classics11252013
pkhohl
 

More from pkhohl (17)

Hyperaldosteronism 3 26-14
Hyperaldosteronism 3 26-14Hyperaldosteronism 3 26-14
Hyperaldosteronism 3 26-14
 
Refractory ARDS
Refractory ARDSRefractory ARDS
Refractory ARDS
 
TF route
TF routeTF route
TF route
 
Early surgery for infective endocarditis
Early surgery for infective endocarditisEarly surgery for infective endocarditis
Early surgery for infective endocarditis
 
Intern talk - BP and stroke
Intern talk - BP and stroke Intern talk - BP and stroke
Intern talk - BP and stroke
 
Surrogate decision making
Surrogate decision makingSurrogate decision making
Surrogate decision making
 
Asdpe disantis
Asdpe disantisAsdpe disantis
Asdpe disantis
 
Iabp 3 6-14
Iabp 3 6-14Iabp 3 6-14
Iabp 3 6-14
 
CNS vasculitis
CNS vasculitis CNS vasculitis
CNS vasculitis
 
Renal infarction morning report 2-10-2014
Renal infarction morning report 2-10-2014Renal infarction morning report 2-10-2014
Renal infarction morning report 2-10-2014
 
Pe massive wilfong
Pe massive wilfongPe massive wilfong
Pe massive wilfong
 
Hypertension- Classics Trobaugh
Hypertension- Classics TrobaughHypertension- Classics Trobaugh
Hypertension- Classics Trobaugh
 
Mediterranean diet primary prevention of cvd journal club
Mediterranean diet primary prevention of cvd journal clubMediterranean diet primary prevention of cvd journal club
Mediterranean diet primary prevention of cvd journal club
 
The challenge of the end of-life discussion housestaff 2014
The challenge of the end of-life discussion housestaff 2014The challenge of the end of-life discussion housestaff 2014
The challenge of the end of-life discussion housestaff 2014
 
Ai morning report 1 21-2014
Ai morning report 1 21-2014Ai morning report 1 21-2014
Ai morning report 1 21-2014
 
Stroke2013update teleron
Stroke2013update teleronStroke2013update teleron
Stroke2013update teleron
 
Hiv classics11252013
Hiv classics11252013Hiv classics11252013
Hiv classics11252013
 

Recently uploaded

Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functions
KarakKing
 
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
ZurliaSoop
 

Recently uploaded (20)

This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024
 
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxHMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
 
Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the Classroom
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functions
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptx
 
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
 
Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
 

Ig a nephropathy

  • 1. IG A NEPHROPATHY GAYATHRI THAMPATTY PGY2
  • 2.
  • 3. • MOST COMMON LESION FOUND TO CAUSE PRIMARY GLOMERULONEPHRITIS THROUGHOUT MOST DEVELOPED COUNTRIES OF THE WORLD • MAY PRESENT AT ANY AGE, PEAK INCIDENCE IN THE SECOND AND THIRD DECADES OF LIFE. THERE IS APPROXIMATELY A 2:1 MALE TO FEMALE PREDOMINANCE IN NORTH AMERICAN AND WESTERN EUROPEAN POPULATIONS
  • 4. • THE REPORTED INCIDENCE OF MESANGIAL IGA DEPOSITION IN APPARENTLY HEALTHY INDIVIDUALS RANGES FROM 3 TO 16 PERCENT . THESE CASES HAD NO CLINICAL FEATURES OF NEPHRITIS BUT THEIR RENAL BIOPSY WAS CONSISTENT WITH IGA NEPHROPATHY. • THIS OBSERVATION RAISES THREE IMPORTANT POINTS: ●THERE IS A LARGE COHORT OF UNDIAGNOSED "LATENT" IGA NEPHROPATHY IN THE GENERAL POPULATION. ●THIS MUST BE TAKEN INTO ACCOUNT WHEN GENETIC STUDIES ARE UNDERTAKEN COMPARING GENE POLYMORPHISMS IN IGA NEPHROPATHY WITH NORMAL "HEALTHY" POPULATIONS. ●PROCESS OF MESANGIAL IGA DEPOSITION IS LIKELY TO BE SEPARATE FROM THE INDUCTION OF GLOMERULAR INJURY AND IGA DEPOSITION DOES NOT NECESSARILY NEED TO BE FOLLOWED BY NEPHRITIS-
  • 5. IGA DEPOSITION IN OTHER FORMS OF GLOMERULONEPHRITIS- THIN BASEMENT MEMBRANE NEPHROPATHY, LUPUS NEPHRITIS, MINIMAL CHANGE DISEASE, AND DIABETIC NEPHROPATHY. MOST PROBABLY DUE TO CHANCE ASSOCIATIONS, SINCE IGA DEPOSITION IS COMMON IN THE GENERAL POPULATION LUPUS NEPHRITIS COULD ALSO HAVE ASSOCIATED PROMINENT MESANGIAL IGA DEPOSITION. LUPUS CAN BE DISTINGUISHED FROM IGA NEPHROPATHY HISTOLOGICALLY BY THE MORE PROMINENT DEPOSITION OF IGG THAN IGA AND THE PRESENCE OF SUBSTANTIAL C1Q DEPOSITION, INDICATING ACTIVATION OF THE CLASSIC COMPLEMENT PATHWAY, AS OPPOSED TO THE ALTERNATE PATHWAY ACTIVATION IN IGA NEPHROPATHY
  • 6. LIGHT MICROSCOPY • MAJOR FINDING - FOCAL (INVOLVING LESS THAN 50 PERCENT OF GLOMERULI) OR MORE OFTEN DIFFUSE MESANGIAL PROLIFERATION AND MATRIX EXPANSION
  • 7. ELECTRON MICROSCOPY • ELECTRON-DENSE DEPOSITS THAT ARE PRIMARILY LIMITED TO THE MESANGIUM (WHICH ARE OUTSIDE OF MESANGIAL CELLS IN THE MESANGIAL SPACES) BUT MAY ALSO OCCUR IN THE SUBENDOTHELIAL AND SUBEPITHELIAL SPACES. THE NUMBER AND SIZE OF THESE DEPOSITS GENERALLY CORRELATES WELL WITH THE SEVERITY OF CHANGES SEEN ON LIGHT MICROSCOPY
  • 8. CLINICAL FEATURES • APPROXIMATELY 40 TO 50 PERCENT - ONE OR RECURRENT EPISODES OF VISIBLE HEMATURIA, USUALLY FOLLOWING A URI (SYNPHARYNGITIC HEMATURIA). PATIENTS MAY COMPLAIN OF FLANK PAIN, LOW GRADE FEVER- MIMIC URINARY TRACT INFECTION OR UROLITHIASIS. MOST PATIENTS HAVE ONLY A FEW EPISODES OF VISIBLE HEMATURIA AND EPISODES USUALLY RECUR FOR A FEW YEARS AT MOST. • 30 TO 40 PERCENT HAVE MICROSCOPIC HEMATURIA AND USUALLY MILD PROTEINURIA, AND ARE INCIDENTALLY DETECTED ON A ROUTINE EXAMINATION . THESE PATIENTS, THE DISEASE IS OF UNCERTAIN DURATION. GROSS HEMATURIA WILL EVENTUALLY OCCUR IN 20 TO 25 PERCENT OF THESE PATIENTS. • LESS THAN 10 PERCENT PRESENT WITH EITHER NEPHROTIC SYNDROME OR ACUTE RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS PICTURE CHARACTERIZED BY EDEMA, HYPERTENSION, AND RENAL INSUFFICIENCY AS WELL AS HEMATURIA. RARELY, IGA NEPHROPATHY MAY PRESENT WITH MALIGNANT HYPERTENSION
  • 9. • CIRRHOSIS, CELIAC DISEASE, AND HIV INFECTION ARE ALL ASSOCIATED WITH A HIGH FREQUENCY OF GLOMERULAR IGA DEPOSITION
  • 10. • NEPHROTIC SYNDROME IN IGA NEPHROPATHY - USUALLY INDICATIVE OF ADVANCED DISEASE. SOME PATIENTS HAVE AN ACUTE ONSET OF THE NEPHROTIC SYNDROME IN WHICH THERE IS ONLY MILD MESANGIAL PROLIFERATION ON RENAL BIOPSY AND THE MOST PROMINENT FINDING IS DIFFUSE FUSION OF THE FOOT PROCESSES, SIMILAR TO THAT SEEN IN MINIMAL CHANGE DISEASE . FURTHERMORE, MANY OF THESE PATIENTS BEHAVE AS IF THEY HAVE MINIMAL CHANGE DISEASE, WITH REMISSION OF PROTEINURIA BEING INDUCED BY GLUCOCORTICOID THERAPY.
  • 11. INDICATIONS FOR RENAL BIOPSY • A KIDNEY BIOPSY IS USUALLY PERFORMED FOR THE EVALUATION OF SUSPECTED IGA NEPHROPATHY ONLY IF THERE ARE SIGNS SUGGESTIVE OF MORE SEVERE OR PROGRESSIVE DISEASE SUCH AS PROTEIN EXCRETION ABOVE 0.5 TO 1 G/DAY, ELEVATED SERUM CREATININE CONCENTRATION, OR HYPERTENSION
  • 12. • PATIENTS WHO HAVE RECURRENT EPISODES OF GROSS HEMATURIA WITHOUT PROTEINURIA ARE AT LOW RISK FOR PROGRESSIVE KIDNEY DISEASE COMPARED WITH PATIENTS WHO HAVE PERSISTENT MICROSCOPIC HEMATURIA AND PROTEINURIA. IN ADDITION, ISOLATED PERSISTENT HEMATURIA (IE, WITH LITTLE OR NO PROTEINURIA) AT PRESENTATION MAY BE ASSOCIATED WITH PROGRESSIVE DISEASE OVER TIME
  • 13. • ISOLATED HEMATURIA, NO OR MINIMAL PROTEINURIA (LESS THAN 500 TO 1000 MG/DAY), AND A NORMAL GLOMERULAR FILTRATION RATE (GFR) ARE TYPICALLY NOT TREATED AND OFTEN NOT BIOPSIED AND THEREFORE NOT IDENTIFIED AS HAVING IGA NEPHROPATHY. NEEDS PERIODIC MONITORING AT 6- TO 12-MONTH INTERVALS SINCE THERE IS AN APPRECIABLE RATE OF PROGRESSIVE DISEASE AS MANIFESTED BY INCREASES IN PROTEINURIA, BLOOD PRESSURE, AND/OR SERUM CREATININE. • ●PATIENTS WITH PERSISTENT PROTEINURIA (ABOVE 1 G/DAY OR PERHAPS ABOVE 500 MG/DAY), A NORMAL OR ONLY SLIGHTLY REDUCED GFR THAT IS NOT DECLINING RAPIDLY, AND ONLY MILD TO MODERATE HISTOLOGIC FINDINGS ON RENAL BIOPSY ARE INITIALLY MANAGED WITH NONIMMUNOSUPPRESSIVE THERAPIES TO SLOW PROGRESSION. • •ANGIOTENSIN INHIBITION WITH EITHER AN ACE INHIBITOR OR ARB. THE GOALS OF THERAPY WITH AN ACE INHIBITOR OR ARB ARE A URINARY PROTEIN EXCRETION BELOW 500 MG/DAY OR 1 G/DAY AND A BLOOD PRESSURE LESS THAN 130/80 MMHG. • •FISH OIL (3.3 GRAMS/DAY OR MORE) CAN BE TRIED IN PATIENTS WITH PROTEIN EXCRETION ABOVE 1 G/DAY DESPITE THREE TO SIX MONTHS OF THERAPY WITH AN ACE INHIBITOR OR ARB.
  • 14. THE INDICATIONS FOR THE USE OF GLUCOCORTICOIDS ALONE OR IN COMBINATION WITH OTHER IMMUNOSUPPRESSIVE DRUGS• NOT WELL DEFINED • MOST NEPHROLOGISTS DO NOT TREAT MILD, STABLE, OR VERY SLOWLY PROGRESSIVE IGA NEPHROPATHY WITH GLUCOCORTICOIDS OR OTHER IMMUNOSUPPRESSIVE THERAPIES • IN GENERAL, ANTI-INFLAMMATORY THERAPY WITH GLUCOCORTICOIDS IN PATIENTS WITH CLINICAL FEATURES SUPPORTING ACTIVE DISEASE AND PROGRESSION, WHICH INCLUDE HEMATURIA IN ADDITION TO ONE OR MORE OF THE FOLLOWING: • ●A PROGRESSIVELY DECLINING GLOMERULAR FILTRATION RATE • ●PERSISTENT PROTEINURIA ABOVE 1 G/DAY AFTER MAXIMAL ANTIPROTEINURIC THERAPY WITH ACE INHIBITORS OR ARBS FOR THREE TO SIX MONTHS • ●MORPHOLOGIC EVIDENCE OF ACTIVE DISEASE BASED ON KIDNEY BIOPSY (EG, PROLIFERATIVE OR NECROTIZING GLOMERULAR CHANGES)